NUVISAN receives US$9.6m grant for a multi-target drug discovery program on novel non-hormonal contraceptive medicines
20 Sep 2022
NUVISAN's integrated drug discovery expertise leveraged in a grant from the Bill & Melinda Gates Foundation
BERLIN, Sept. 20, 2022 /PRNewswire/ -- NUVISAN ICB GmbH, a fully integrated contract research service provider for drug discovery and development ("NUVISAN ICB"), announced today that the company has received a grant with the Bill & Melinda Gates Foundation (Seattle, WA, USA, "the foundation") for an integrated program on discovery and early development of novel non-hormonal contraceptive medicines.
NUVISAN has been awarded a three-year grant of US$ 9.6 million from the foundation to develop a portfolio of programs based on several promising human protein targets, establish tools and assays, perform high-throughput screening (HTS) of a library of up to 2.46 million compounds to identify chemical hits that are suitable for pharmacological intervention, and further optimize these hits to in vivo lead compounds during the hit-to-lead process.
"Addressing the unmet family planning and birth control needs of women and their families worldwide is a global challenge and an exciting motivation for us at NUVISAN", according to Arnoud Huisman, Managing Director of NUVISAN ICB and Chief Strategy Officer of the NUVISAN group, "We appreciate the foundation's trust and are delighted to contribute our scientists' long-standing pharma expertise and our integrated drug discovery and development capabilities to this program, to eventually bring new non-hormonal contraceptive medicines to the clinic."
About NUVISAN
The NUVISAN group is a Contract Research and Development & Manufacturing Organization (CRO/CDMO) with six sites in Germany and France. NUVISAN offers unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain - from target to patient. Thanks to more than 40 years of experience and over 1,000 employees, NUVISAN supports its biotech startup, pharma, and venture capital partners to discover, develop, and bring the next generation medicines to market.
NUVISAN ICB GmbH (Innovation Campus Berlin) was acquired by NUVISAN as a fully functional pharma R&D unit in 2020. NUVISAN ICB brings decades of successful drug discovery and development expertise in a broad indication spectrum including women's and men's health, oncology, and cardiovascular diseases. With all capabilities located under one roof in Berlin, NUVISAN ICB provides end-to-end solutions from target identification to pre-clinical candidates and IND, covering protein technologies, structural biology, high-throughput screening, computational and medicinal chemistry, pharmacology, translational research, drug metabolism & pharmacokinetics as well as toxicology.
With a recent strategic investment from ALS LimitedALS Limited (ASX: ALQ), the NUVISAN group is today one of the fastest growing companies in the industry for the benefit of its partners and the patients they cure. For more information, please visit www.nuvisan.com
Nuvisan media contact
Uyen.Nguyen ; [email protected], +49 172 4166247
Logo - https://mma.prnewswire.com/media/1902191/Nuvisan_Logo.jpg
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.